This is a 24-week randomized, double-blind, placebo-controlled Phase 2 clinical study with a 28-week extension to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of 3 dose levels of solrikitug versus placebo on top of standard of care in adult participants with EoE.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
106708
Trial contact details
-
Contact person
IBD Clinical Trials Team
What you need to know
Who can take part?
To participate you must:
Be aged 18-75
Weigh 40kg or more
Have a confirmed diagnosis of Eosinophilic Esophagitis
Have difficultly swallowing
Have a stable diet for at least 4 weeks
Be on a stable dose of your current treatment
Have blood & urine test results within standard ranges
Not be pregnant or planning pregnancy
Not have a current or recent infection
Not be undergoing Immunosuppression treatment
Not have a previous cancer diagnosis
Not have failed treatment with dupilumab
Not have strictures
Certain medications may make you ineligible to participate
What is involved for me?
Medical history and collection of demographic information
Vital signs
Electrocardiogram
Physical exam
Blood and urine tests
Pregnancy tests for women with childbearing potential
Endoscopy with esophagus tissue biopsy
Daily diary completion
Questionnaires
Treatment by sub-cutaneous injections
